OVK18Homo sapiens (Human)Cancer cell line
Also known as: OVK#18, OVK-18
Quick Overview
OVK18 is a human ovarian endometrioid carcinoma cell line established from ascitic fluid, used for cancer research and drug dev...
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3770 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ascites[UBERON:UBERON_0007795] |
Donor Information
| Age | 49 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Endometrioid carcinoma of ovary |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Endometrioid Ovarian Cancer |
| OncoTree Code | EOV |
DepMap Information
| Source Type | RIKEN |
|---|---|
| Source ID | ACH-000947_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Pro152Argfs*18 (c.455delC) | Heterozygous | - | from parent cell line OVK18 |
| MutationSimple | SMARCA4 | p.Pro109fs*194 (c.322delC) | Heterozygous | - | from parent cell line OVK18 |
| MutationSimple | SMAD2 | p.Tyr366fs*17 (c.1096delT) | Heterozygous | - | from parent cell line OVK18 |
| MutationSimple | KRAS | p.Ala59Gly (c.176C>G) | Heterozygous | - | from parent cell line OVK18 |
| MutationSimple | JAK2 | p.Leu437fs*1 (c.1305delT) | Heterozygous | - | from parent cell line OVK18 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.
Sci. Rep. 10:10799-10799(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Miyazaki K.
Hum. Pathol. 43:2197-2206(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).